The goal of this project is to develop an initial verification of a new method for the treatment of multiple sclerosis (MS), an autoimmune disease. About 900-1000 people are diagnosed with MS every year in Sweden. Current treatments are ineffective and often not specific for MS, and can lead to

The lung disease COPD, according to WHO, is the fourth most common cause of death worldwide, and its prevalence is increasing. Of the more than 200 million people suffering from COPD, three million die annually. The diagnostic method that is most specific for emphysema is computed tomography (CT scan) –

Pancreatic cancer is one of the most serious forms of cancer. The difficulty is to identify pancreatic cancer “early”. There are no biomarkers in either blood or tissue to provide diagnosis, prognostic / predictive help and support in selecting therapy. Research has now found a pancreatic cancer-specific marker (Histone 1.3;

Glioblastoma is the most common primary brain tumour in humans. It is a diagnosis with a very bleak outcome. The goal is to analyse whether glioblastoma expresses C1-IA and CRP (proteins) that inhibit immune response by inactivating the complement system, and to test treatment in various animal models for glioblastoma.

The incidence of bladder cancer is on the increase in Sweden. The purpose of the project is to apply molecular classification with RNA sequencing technology in clinical practice to bladder cancer cases. By analysing the expression of every gene in the tumour cells, bladder cancer can be classified into subtypes,

Ovarian cancer is the main cause of death from gynaecological malignancies in the western world. The aim of the study is to develop a non-invasive diagnostic test for pre-symptomatic diagnosis of ovarian cancer. Early detection would have a profound effect on survival, which enables curative treatment for these patients. Achieving

Mucopolysaccharide Type I (MPS-I) belongs to the wider group of lysosomal storage disorders. The most serious form is Hurler’s syndrome. None of the available interventions for MPS-I modify central nervous system pathology, while the proposed drug reaches CNS. The subject is not yet an approved drug, but it is now

Type 1 diabetes (T1D) is an autoimmune disease where activation of the immune system causes the cells in the pancreas that produce insulin to be destroyed. The project aims to develop a drug that can significantly reduce the risk of hypo / hyperglycaemia and sequelae; a peptide drug that will

The purpose of this project is to develop a vaccine for the treatment of MS. Treatment of MS in an animal model has been successful. The aim is to take this vaccine to market. Today’s medicines for autoimmune diseases are ineffective and not without side effects. There is, therefore, a

The project aims at initiating and implementing a Phase II trial in order to investigate whether an already approved diagnostic drug can be used for the detection of kidney cancer. Diagnostics could in a conclusive way contribute to a more detailed analysis of the metastasis in these patients than is